Bristol-Myers Bags Biotech Upstart Padlock in $600M Autoimmune Deal

Wednesday, March 23, 2016

Source: FierceBiotech

Bristol-Myers Squibb ($BMY) has struck a $600 million deal to buy out the biotech startup Padlock Therapeutics and its autoimmune R&D platform. 

Fostered by Atlas Venture and a band of dedicated biotech investors, Padlock set out to disrupt the entire autoimmune field with a new approach to preventing a process in which the immune system mounts an errant attack on healthy tissue.

Diseases like rheumatoid arthritis can be stopped by halting protein citrullination, Padlock's founders believe, in which healthy tissue becomes an antigen targeted for an immune system attack. And you can stop the process by targeting enzymes called protein-arginine deiminases, or PADs, with the small molecules the biotech hunted for.

View All News »